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INTRODUCTION
Churg-Strauss syndrome (CSS), also known as allergic
granulomatous angiitis, is a systemic necrotizing vasculi-
tis of the small and medium vessels. It typically occurs
in conjunction with a history of asthma, eosinophilia,
pulmonary infiltrates, and vasculitis, but cases without
asthma have also been reported (1-2). CSS has rarely
been reported in pediatric patients. Here, we report
a nine-year-old boy with a possible diagnosis of CSS
who presented with prominent pulmonary involvement
accompanied by eosinophilia, rash, abdominal pain, and
hepatomegaly but without anti-neutrophil cytoplasmic
antibody (ANCA). The present case indicates that physi-
cians should consider CSS when eosinophilia is noted in
bronchoalveolar lavage, serum, or a tissue specimen. The
clinical features and treatment for childhood CSS are
reviewed.
CASE DESCRIPTION
A nine-year-old boy presented to our clinic with a one-
week history of a productive cough, blood-streaked sputum
and increased wheezing and a five-day history of fever. He
complained of a one-year history of asthma, which had
previously been treated with inhaled corticosteroids with the
addition of montelukast. A BCG scar confirmed previous
immunization against tuberculosis. He had no history of
travel to helminth endemic areas and showed no weight loss.
The boy was admitted because of the exacerbation of his
symptoms and a chest radiograph revealing infiltration in
both lungs in April 2011 (Figure 1A). The possibility of
pneumonia was considered. After taking a five-day course of
antibiotics, which included ceftriaxone for five days and
azithromycin for three days, his respiratory symptoms and
physical condition improved. However, several days later,
his condition worsened, with cough, severe dyspnea, perioral
cyanosis, urticaria-like lesions and vesicular rashes on the
skin of both lower extremities, and purpura on the hands.
Additionally, he began to experience lower back pain, whole
body fatigue, pyknocardia, hepatomegaly, mild splenome-
galy, hyperpyrexia, bilateral swelling of the parotid gland,
submaxillary gland enlargement, discrete cervical lympha-
denectasis, acute abdominal pain, chest pain, polyarthralgia,
myalgia, and muscle weakness. His chest X-ray demon-
strated worsening of the pulmonary infiltration (Figure 1B).
The initial laboratory examination at the time of admis-
sion showed a peripheral white blood cell (WBC) count of
14.96109/L (normal: 4-106109/L) with 30.7% eosinophils
(normal: 0%–5%), 41.4% neutrophils, 21.6% lymphocytes,
and a hemoglobin level of 138 g/L. Notably, 11 days later,
his eosinophil count increased to 72.2% with an absolute
eosinophil count of 27.96109/ L and a WBC count of
38.66109/L. The patient’s erythrocyte sedimentation rate
was 77 mm/hour, and immunoglobulin E (IgE) was
elevated to 1258 KU/L (reference range: 0–100 KU/L).
Tests for cytoplasmic (classical) antineutrophil cytoplasmic
antibodies (c-ANCA) and peri-nuclear (protoplasmic-stain-
ing) antineutrophil cytoplasmic antibodies (p-ANCA) were
negative. The levels of proteinase 3 (PR3) and myeloperox-
idase (MPO) were normal. Computed tomography of the
chest demonstrated interstitial infiltration. Cultures and/or
stains of blood and sputum for viruses, fungi, acid-fast
bacilli and bacteria were all negative. His parents declined
bone marrow aspiration. A peripheral blood smear analysis
produced normal results. His lactate dehydrogenase level
was 235 U/L (normal, 120-300 U/L). Peripheral blood
lymphocyte immunophenotyping indicated that his T-cell
subsets were normal. All tumor markers and antinuclear
antibodies were negative. Stool cultures for parasites and
the results of serum analyses for anti-Schistosoma and anti-
Sparganum species antibodies were all negative, and serum
samples were negative for HIV and hepatitis B and C. No
other significant laboratory abnormalities were found,
including blood gas levels, hepatic, renal and myocardial
function, coagulation function, antistreptolysin o, comple-
ment levels, 1-3-b-D glucosan (G test) and galactomannan
(GM test). Cardiac evaluations, including electrocardiogra-
phy and echocardiography, revealed no abnormalities.
A skin biopsy specimen obtained from a rash on the
patient’s left lower extremity revealed a dermal infiltration
with a considerable quantity of eosinophils (Figure 2A).
Flexible bronchoscopy revealed moderate secretions. Bron-
choalveolar lavage cytology revealed a predominance of
in flammatory cells with 93% eosinophils, 2% macroph-
ages (Figure 2B), and no microorganisms. A diagnosis of
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Churg-Strauss syndrome (CSS) was suggested. Corticosteroid
therapy (intravenous methylprednisolone) was initiated at a
dose of 80 mg daily (2.7 mg/kg/day), which improved the
symptoms. Five days later corticosteroid (methylprednisolone
tablets) was tapered at 48 mg daily (1.7 mg/kg/day). After
two weeks of corticosteroids treatment, his condition stabi-
lized and a peripheral eosinophil count decreased to 1.3%,
WBC count decreased to 8.076109/L, and the sedimentation
rate decreased from 77 to 16 mm/hour. Chest computed
tomography (Figure 1C) and x-ray (Figure 1D) revealed an
improvement in pulmonary infiltration. Ten months later, the
last flexible fiberoptic examination showed a clear airway,
and the bronchoalveolar lavage cytology assay was normal.
The corticosteroids were tapered without any systemic
vasculitis over the following 11 months. At the latest follow
up in late February 2012, the child was started on methyl-
prednisolone tablets at a dose of 8 mg daily (0.3 mg/Kg/day)
for two months.
DISCUSSION
Churg-Strauss syndrome was first described by Churg
and Strauss in 1951 (3). The annual incidence of CSS in
adults ranges between 0.5 and 3.1 cases per million. In
children, the incidence of CSS is unknown but is thought to
be very low. To our knowledge, only 44 pediatric patients
with CSS have been reported, including our present case.
The reported patients’ ages ranged from 2 to 18 years (20
males and 24 females), with clinical manifestations rarely
appearing before one year of age.
The rarity of CSS in childhood makes the diagnosis much
more difficult. In 1990, the American College of
Rheumatology (ACR) developed specific clinical criteria
for the classification of CSS, which comprised a history of
asthma, eosinophilia .10%, mononeuropathy/polyneuro-
pathy, nonfixed pulmonary infiltrates, paranasal sinus
abnormality, and extravascular eosinophils revealed by
biopsy. The presence of at least four criteria yields a
sensitivity of 85% and a specificity of 99.7% (4). Our patient
met four of the six ACR criteria, namely, a history of asthma,
eosinophilia .10%, pulmonary infiltrates, and a skin biopsy
revealing extravascular eosinophils. However, although
commonly used to diagnose CSS, the ACR criteria were
not meant as diagnostic criteria and were instead meant
to distinguish one form of vasculitis from another.
Unfortunately, there have been no new diagnostic criteria
for CSS. The differential diagnosis of CSS depends on the
predominant clinical manifestations of each patient. For
example, hypereosinophilic syndrome (HES) is difficult to
distinguish from CSS because HES patients may have
hypereosinophilia and end-organ damage, but characteris-
tics such as asthma, atopic history and lung infiltrates
support a diagnosis of CSS. Concomitant eosinophilia,
asthma, and lung infiltrates may resemble certain parasitic
infections, but stool cultures for parasites and serum
analyses for antibodies were negative, and our patient had
no history of travel to helminth endemic areas. Moreover,
neoplastic disorders, particularly lymphomas, typically
progress by the 11-month follow-up examination, but our
patient’s prompt response to treatment and persistent
remission did not support the diagnosis of neoplastic
disease. Nevertheless, a definite diagnosis was a challenge,
and we still follow up with the patient in the event that
evidence of a malignant disorder is discovered. The accurate
diagnosis of CSS requires the presence of a constellation of
findings that may have presented and evolved over a period
of years rather than any individual pathological finding at
one time point (5-7).
After reviewing the 43 cases of pediatric CSS in the
literature, we outlined the clinical features of CSS in children
and compared them with those in adults. The mortality rate of
CSS is approximately 5% in adults (8) and is significantly
worse in children, at 15.9% (7/44). In the past four years, 2 of
the 11 pediatric CSS patients died due to pulmonary abscess
and sepsis despite treatment with immunosuppressive drugs
and intravenous immunoglobulin (1,9). The other predomi-
nant causes of death include heart failure, renal failure,
cerebral failure, and gastrointestinal perforation/hemorrhage.
In our review, a history of asthma was found in 39 (88.6%)
of the 44 children with CSS. Almost all CSS patients show a
marked peripheral blood eosinophilia. The highest absolute
eosinophilic count reported in all ages was 51.66109/L and
leukocytosis in leukemic ranges (65.86109/L) (10). In our
Figure 2 - A) A skin biopsy showing the accumulation
of extravascular eosinophilic infiltrates (hematoxylin-eosin
stain 6200). B) Bronchoalveolar lavage fluid (BALF) showing
a considerable quantity of eosinophils (Giemsa staining
6200).
Figure 1 - Radiological imaging. A) A computed tomography
scan showing pulmonary infiltrates in both lungs. B) A chest
x-ray showing aggravation. C) A computed tomography
scan showing improvement. D) A chest x-ray showing
improvement.
Churg-Strauss syndrome in a child
Liu J et al.
CLINICS 2012;67(8):977-980
978
patient, the highest level of leukocytosis was 38.66109/L
with an absolute eosinophil count of 27.96109/L (72.2%). Of
the 44 pediatric CSS patients, 23 had high IgE levels and
only 2 had normal IgE levels; the 19 remaining cases lacked
relevant data. Our patient was negative for ANCAs, which
is consistent with the literature demonstrating that only 5 of
23 patients were positive for ANCAs. However, the
frequency of ANCA positivity is uncertain because the
ANCA status was not available for the other 21 children.
Two recent independent studies on large cohorts have
found that ANCAs are present in only approximately 40%
of adult CSS patients (11,12). It has been postulated (11,12)
that CSS might encompass two clinical subsets or pheno-
types: one is an ANCA-associated process that primarily has
the features of small-vessel vasculitis (such as glomerulone-
phritis, mononeuritis multiplex, and purpura), and the
other is ANCA-negative and more related to eosinophilic
tissue infiltration that leads predominantly to pulmonary
involvement and cardiopulmonary manifestations.
The clinical presentation of CSS is variable, and virtually
any organ can be affected by the disease. In our review,
pneumonia was the most common disorder (37/44 cases;
84.1%) followed by cutaneous manifestations (29/44,
65.9%). Skin manifestations were a common early presenta-
tion of CSS in children, which ranged from discrete to
diffuse patchy, petechial or purpuric lesions and can be
itchy, edematous, or tender. Paranasal sinus abnormalities
were also common early presentations (24/37; 64.9%).
Neurologic involvement, especially multiple mononeuro-
pathy, was described in 40.5% (17/42) of children with CSS
and has been reported in 36% of adult patients with CSS (8).
Heart involvement was reported in 38.6% (17/44) of the
children, gastrointestinal tract involvement in 34.1% (15/44)
and kidney involvement in 13.6% (6/43). A number of
reports reveal more subtle presentations of CSS, including
swelling of the legs and feet, oral aphthae, hepatomegaly,
hepatic venous outflow obstruction, respiratory distress,
polyarthralgia, myalgia, polyneuropathies presenting as
dysesthesia, muscle weakness, gait disturbances, venous
thrombosis and pulmonary embolism, hemichorea, sudden
painless loss of vision, retinal artery occlusions, discrete
cervical lymphadenopathy, testicular pain, hypertension,
seizures and necrosis of the toe tips.
Although the diagnosis of CSS is established mainly
based on clinical observations, a tissue biopsy should be
performed whenever possible (5,13). In addition to skin
biopsies, the diagnosis of CSS is increasingly aided by
transbronchial lung biopsy, open or thoracoscopic lung
biopsy and, less frequently, by sinus biopsy, nasal mucosa
biopsy or liver biopsy. A controlled study for the optimal
treatment of CSS is not yet available because of the limited
number of patients. The cornerstone of treatment for CSS
remains corticosteroid therapy, but the response is variable.
In patients with severe organ involvement or uncontrolled
vasculitis symptoms, additional therapy with cyclopho-
sphamide and/or azathioprine chlorambucil and metho-
trexate is required. The use of these various immuno-
suppressive medications was effective in treating refractory
CSS and in minimizing relapses. Plasma exchange was also
used as an alternative to cytotoxic therapy, but prospective
studies have not shown any difference in mortality or
outcome (5). Moreover, intravenous immunoglobulin is a
treatment option in patients with CSS with neuropathy (14).
Rituximab, in fliximab, MMF (mycophenolate mofetil), and
a-interferon are other therapeutic options used to treat CSS
(15).
In conclusion, our present case emphasizes the impor-
tance of considering the diagnosis of CSS in children with
uncontrolled pneumonia, hypereosinophilia, skin lesions,
neuropathy, cardiomyopathy or hepatomegaly in conjunc-
tion with a previous history of asthma and sinusitis.
Delayed diagnosis and severe organ involvement may
worsen the prognosis and even lead to a fatal outcome.
If started early, treatment with corticosteroids is often
successful.
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